AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03083509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercise weight training session
Description: A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
Study NCT03181191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test and biopsies
Study NCT03083509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-Intensity stochastic cycling session
Description: A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
Study NCT01370148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conivaptan hydrochloride
Description: Intravenous
Study NCT01370148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: Intravenous
Study NCT03982160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
Study NCT03982160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04422496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study.
Study NCT04422496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC96719
Description: single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study.
Study NCT03083509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simulated Team sport protocol
Description: A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
Study NCT03395275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Tests
Description: Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results.
Study NCT04326738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
Study NCT04326738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: N group received corresponding intravenous normal saline of1ml·kg-1 .
Study NCT03395275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surveys
Description: surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
Study NCT03579524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
Study NCT03579524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
Study NCT05504122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair
Description: Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
Study NCT05504122 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inguinal hernia repair
Description: Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
Study NCT03448211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-toluenesulfonamide Injection (PTS)
Description: Intratumoral injection
Study NCT02652221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Imaging
Description: ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
Study NCT01877304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKITA
Study NCT01877304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKITA
Study NCT02095106 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Waterproof Cast
Study NCT02095106 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional cast
Study NCT03198754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEI Experimental Light
Description: Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Study NCT02546323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20mg tablets, orally once daily for the duration of the 104-week treatment period
Study NCT02546323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
Study NCT02874729 — intervention group
Intervention type: PROCEDURE
Intervention: Venesection
Description: Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
Study NCT02874729 — intervention group
Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected in appropriate sterile holders provided.
Study NCT03198754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Light
Description: Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Study NCT02307071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly Kit Arnold
Description: Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
Study NCT02874729 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Saliva will be collected in appropriate sterile holders provided.
Study NCT02874729 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
Study NCT02578082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: A single inhaled dose of TD 4208 (175 mcg)
Study NCT01083602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
Study NCT01083602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT01083602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00672997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution
Study NCT00672997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
Study NCT02299063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
Study NCT02299063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study NCT05692778 — intervention group
Intervention type: OTHER
Intervention: Patients being foot examined by using an eHealth tool
Description: Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
Study NCT05692778 — intervention group
Intervention type: OTHER
Intervention: Patients being foot examined in traditional manner
Description: Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
Study NCT01211093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frequency whole body vibration
Description: 1 single session (10 minutes) of whole body vibration therapy at 30 Hz
Study NCT01211093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency whole body vibration
Description: 1 single session of whole body vibration therapy at 20 Hz
Study NCT01211093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 1 single session of standing on the vibration platform, with no vibration signals delivered.
Study NCT02957136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid respiratory pathogen nucleic acid amplification test
Description: Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
Study NCT04444258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of computer aided virtual reality glasses
Description: Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
Study NCT04444258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching fetal development theoretically
Description: Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
Study NCT00405535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycine
Study NCT00405535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04260334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Education
Description: The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
Study NCT03976115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055
Description: Oral
Study NCT03976115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral
Study NCT01428518 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine tablets
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study NCT02082145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
Study NCT01794481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Description: If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique.
Study NCT02143193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin Contact
Study NCT04069741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: A website that contains information about de Quervain's tenosynovitis and the options for treatment
Study NCT04069741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: A website that contains information about de Quervain's tenosynovitis and the options for treatment
Study NCT04069741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toolkit for de Quervain's
Description: A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
Study NCT03594487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMP30 Donor Stool
Description: FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
Study NCT03594487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool
Description: Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
Study NCT03594487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observational Control
Description: Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
Study NCT01841996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 solution
Description: Once a day for 28 days
Study NCT01841996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Once a day for 28 days
Study NCT01999192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tregalizumab
Description: humanized anti-CD4 mAb
Study NCT01999192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical end formulation buffer
Study NCT03483948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523 tablet
Study NCT03483948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine Injection
Study NCT03942081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulcer Measurement Software
Description: Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
Study NCT02841787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for late life depression
Study NCT01651468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HEMOFIX
Description: unique complex herbal mixture
Study NCT02986269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia across LMA
Description: general anesthesia across LMA
Study NCT02986269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia across LMA
Description: general anesthesia across LMA
Study NCT04497714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic image collection
Description: Ultrasonic image collection,consist of three static images and one dynamic image
Study NCT02497105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Dietary
Study NCT01127919 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Training
Description: 40 minutes, 3 times a week for 35 weeks.
Study NCT01127919 — intervention group
Intervention type: OTHER
Intervention: Cognitive Component
Description: Provide general information about health and fitness
Study NCT00969423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm videoscope
Description: use of 5mm videoscope
Study NCT00969423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10mm videoscope
Description: use of 10mm videoscope
Study NCT00718315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily
Study NCT00718315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fusidic acid [Verutex]
Description: topical, daily for 30 days.
Study NCT00718315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin [Eritex]
Description: topical, daily for 30 days.
Study NCT00718315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisiogel
Description: topical, daily for 30 days
Study NCT02384421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS (Activa PC+S Neurostimulator)